首页 工具
登录
购物车

搜索结果

Search Results for " bsj 04 132 "
Targets Recommended: PROTACs

1

抑制剂 & 化合物

3

重组蛋白

如果没找到您满意的产品或者您对产品有其他要求,可以联系我们专业顾问为您提供针对性的合理建议。     QQ咨询       网站留言咨询

提交您的定制咨询

点击图片重新获取验证码
Cat. No. Product Name Target Signaling Pathways
T35476 BSJ-04-132

PROTACs PROTAC
Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation. Jiang et al (2019) Development of dual and selective degraders of cyclin-dependent kinases 4 and 6. Angew.Chem.Int.Ed.Engl. 58 6321 PMID:30802347

化合物

BSJ-04-132
Cat.No: T35476
Synonym:
Target: PROTACs
Cat. No. Product Name Species Expression System
TMPK-01450 HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated

KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS2B,K-Ras 2,C-K-RAS,RASK2,K-...

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01456 HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)

KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B,KI-RAS,K-Ras 2,RA...

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01451 HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)

NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,CFC2,K-RA...

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

重组蛋白

HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01450
Species: Human
Expression System: HEK293 Cells
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01456
Species: Human
Expression System: HEK293 Cells
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01451
Species: Human
Expression System: HEK293 Cells
TargetMol Loading
联系我们
400-820-0310

上海市静安区江场三路238号8楼